1 Result: Mesoblast
Mesoblast Faces Regulatory Setback; Nikola's Earnings: A Preview
August 04th, 2023
Mesoblast Limited (Nasdaq: MESO) has announced the receipt of a comprehensive response from the US Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) resubmission for remestemcel-L. The FDA's response stipulates the . Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
Treasury Targets Global Scam Networks and the Corporate Infrastructure That Enables Them
November 06th, 2026FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma
November 05th, 2026New Details Emerge in Amazon Ads Auction-Rigging Case
November 05th, 2026November 02nd, 2026
Member Login